Educational guide
End Uncertainty: Break Through the Roadblocks to Monoclonal Antibody (mAb) Characterization
Monoclonal antibodies (mAbs) represent one of the fastest growing classes of drugs in the pharmaceutical industry. As a protein drug, the manufacturing of mAbs from initial expression to commercialization is a highly complex process, requiring careful characte
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Monoclonal antibodies (mAbs) represent one of the fastest growing classes of drugs in the pharmaceutical industry. As a protein drug, the manufacturing of mAbs from initial expression to commercialization is a highly complex process, requiring careful characterization of the mAb at each step. Peptide mapping, among the many analytical methods used for mAb characterization, is an essential technique that provides primary sequence confirmation of the mAb as well as the identification and quantitation of post-translational modifications (PTMs) such as deamidation, oxidation, and glycosylation.
From sample prep, to analytical instruments, to columns, software, and service, Agilent provides you with the tools and support you need to increase efficiency and reduce risk in your workflow for key biopharma applications such as Aggregate Analysis, Charge Variant Analysis and Peptide Mapping.
Increase efficiency and reduce risk in your laboratory with Agilent’s next-level tools. To learn more, contact your Agilent representative today or visit us online at www.agilent.com/en-us/promotions/biopharma.
Sponsored by: